Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Atossa Therapeutics Inc ATOS

Healthcare Biotechnology
Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is engaged in developing medicines in areas of significant unmet medical need in oncology with a focus on using (Z)-endoxifen to prevent and treat breast cancer. Its lead drug candidate under development is oral (Z)-endoxifen, which it is developing for both the prevention and treatment of breast cancer. (Z)-endoxifen... see more

Recent & Breaking News (NDAQ:ATOS)

Atossa Genetics Announces Second Quarter 2018 Financial Results And Provides Company Update

GlobeNewswire August 13, 2018

Atossa Genetics Contracts with Additional Manufacturer of Endoxifen

GlobeNewswire August 1, 2018

Investor Expectations to Drive Momentum within NetApp, eBay, The Boeing, HCP, Atossa Genetics, and Anavex Life Sciences — Discovering Underlying Factors of Influence

GlobeNewswire July 30, 2018

Atossa Genetics Announces Intraductal Microcatheter ImmunoOncology Pre-Clinical Program

GlobeNewswire July 18, 2018

Atossa Genetics Opens Enrollment in Phase 2 Study of Oral Endoxifen to Treat Breast Cancer

GlobeNewswire July 13, 2018

Atossa Genetics Opens Its Phase 2 Study of Topical Endoxifen to Treat Mammographic Breast Density

GlobeNewswire June 26, 2018

Atossa Genetics Completes all Dosing and Clinical Visits in its Phase 1 Study of Topical Endoxifen in Men

GlobeNewswire June 20, 2018

Atossa Genetics Appoints Two Additional Prominent Industry Executives to Strategic Advisory Board

GlobeNewswire June 14, 2018

Atossa Announces $13.4 Million in Expected Gross Proceeds from Recently Expired Rights Offering

GlobeNewswire May 25, 2018

Atossa Genetics Receives Positive Interim Safety Review from Independent Safety Committee in Phase 1 Topical Endoxifen Dose Escalation Study in Men

GlobeNewswire May 15, 2018

Atossa Genetics To Host Corporate Conference Call Wednesday, May 16, 2018 at 4:30pm EDT

GlobeNewswire May 14, 2018

Atossa Genetics Announces First Quarter 2018 Financial Results And Provides Company Update

GlobeNewswire May 14, 2018

Atossa Genetics Supports National Women's Health Week Lead by U.S. Department of Health and Human Services’ Office on Women’s Health

GlobeNewswire May 11, 2018

Atossa Genetics Regains NASDAQ Compliance

GlobeNewswire May 8, 2018

Atossa Genetics Reminds Investors of Today’s Deadline to be a Shareholder of Record

GlobeNewswire May 7, 2018

Atossa Genetics Forms Strategic Advisory Board to Accelerate Growth

GlobeNewswire May 3, 2018

Mid-Afternoon Market Update: Crude Oil Up Over 1%; Financial Engines Shares Spike Higher

Benzinga.com  April 30, 2018

Atossa Genetics Receives Approval from the Swedish Medical Products Agency for Phase 2 Topical Endoxifen Study

GlobeNewswire April 30, 2018

Mid-Afternoon Market Update: Dow Falls Over 200 Points; Limelight Networks Shares Spike Higher

Benzinga.com  April 20, 2018

Mid-Day Market Update: Skechers USA Falls After Weak Q2 Guidance; Ericsson Shares Climb

Benzinga.com  April 20, 2018